Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy
8.6.2026 08:00:00 CEST | Business Wire | Press Release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared.
"PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it."
Physics-accurate, radiobiologically informed planning
PlanOne™ is built on a GPU-accelerated Monte Carlo dose engine for particle therapy, which serves as the physical foundation for accurate LET calculation and variable RBE modelling*. Clinical teams can plan with confidence and can review plans within a single planning workflow.
Full control over plan robustness
PlanOne™ provides comprehensive user-defined robust optimization, analysis and evaluation. Beyond the worst-case scenario approach, PlanOne™ supports an all-scenario scheme across the full set of user-defined scenarios simultaneously, resulting in treatment plans that reflect physical reality without compromising the plan’s robustness.
One environment. The OIS you already have.
Contouring, planning, and review take place within a single environment, and purpose-built tools support the demands of proton and heavy-ion treatment planning. PlanOne™ integrates with existing oncology information systems, helping preserve established workflows while reducing the need for data migration.
About Cosylab
Cosylab is a software and control systems company headquartered in Ljubljana, Slovenia. With over 20 years of experience and more than 1,000 projects across particle accelerators, radiation therapy devices, and oncology information systems, Cosylab develops complex software for the world's most technically demanding environments. PlanOne™ V1.0 is Cosylab's FDA 510(k) cleared treatment planning system for particle therapy.
PlanOne™ V1.0 is FDA 510(k) cleared. Items marked with * are in preparation for regulatory submission or under development; not yet available for sale and/or clinical use in any market. Market availability is subject to regulatory approval. PlanOne is a trademark of Cosylab d.d., registered in the United States and the European Union.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260607163098/en/
Contacts
For more information, contact:
Media contact: Petra Balažic, petra.balazic@cosylab.com
Product info: cosylab.com/planone -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcosylab.com%2F
planone&esheet=54547437&newsitemid=20260607163098&lan=en-US&anchor=cosylab.com%2
Fplanone&index=1&md5=113926ef7b3e8684aaca3857fd6d47db, planone@cosylab.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cegid Closes Acquisition of Shine to Create Europe's First Complete AI-Driven Platform for SMBs and Accountants8.6.2026 09:28:00 CEST | Press Release
Cegid, a European leader in cloud management solutions for professionals in the finance (treasury, tax, ERP), human resources (payroll, talent management), accountancy, retail and entrepreneurship sectors, today announced the completion of its acquisition of Shine. The transaction creates the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe. Shine – a fast-growing European fintech unicorn providing electronic invoicing, accounting, business accounts, and payroll software to small and medium-sized businesses across Europe – brings more than 400,000 SMB customers, a strong brand, and a scalable technology stack, expanding Cegid’s reach in key European markets. The consolidated group will serve more than one million SMBs and 15,000 accountants across France, Germany, Spain, Portugal, Denmark, the Netherlands and Belgium. Shine’s combination with Cegid and its full ecosystem represents the formation of Europe’s first 100% clou
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press Release
ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to operational execution, but organisations cannot scale AI without trust, visibility, and control,” sai
Alvarez & Marsal utökar sin skatteverksamhet till Sverige och ingår avtal med Magnus Pantzar8.6.2026 09:00:00 CEST | Pressmeddelande
Det globala konsultföretaget Alvarez & Marsal (A&M) fortsätter att utöka sin internationella skatteverksamhet genom att etablera ett nytt kontor i Stockholm. Företaget har ingått ett avtal med Magnus Pantzar att tillträda som Managing Director och leda det svenska kontoret med planerad tillträdesdag den 1 augusti 2026. Teamet i Stockholm under Magnus ledning kommer att bistå svenska och internationella kunder däribland private equityinvesterare och portföljbolag, förvaltare av alternativa investersfonder, multinationella företag samt ägarledda och snabbväxande företag och dess nyckelpersoner. Teamet kommer att tillhandahålla transaktionsrelaterad rådgivning, fondstrukturering, allmän skattestrukturering och rådgivning inom Private Capital, såsom incitamentsprogram och värdeskapande förberedelser inför avyttring och börsintroduktion samt övrig internationell beskattning. Etableringen i Stockholm möter den växande efterfrågan från kunder på oberoende skatterådgivning. ”Sverige är ett vik
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press Release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom